JP2012525335A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525335A5
JP2012525335A5 JP2012507474A JP2012507474A JP2012525335A5 JP 2012525335 A5 JP2012525335 A5 JP 2012525335A5 JP 2012507474 A JP2012507474 A JP 2012507474A JP 2012507474 A JP2012507474 A JP 2012507474A JP 2012525335 A5 JP2012525335 A5 JP 2012525335A5
Authority
JP
Japan
Prior art keywords
alkyl
piperazin
benzamide
pyridin
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525335A (ja
JP5741574B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032477 external-priority patent/WO2010126851A1/en
Publication of JP2012525335A publication Critical patent/JP2012525335A/ja
Publication of JP2012525335A5 publication Critical patent/JP2012525335A5/ja
Application granted granted Critical
Publication of JP5741574B2 publication Critical patent/JP5741574B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012507474A 2009-04-27 2010-04-27 Ｃｘｃｒ３受容体アンタゴニスト Expired - Fee Related JP5741574B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17286909P 2009-04-27 2009-04-27
US61/172,869 2009-04-27
US31735110P 2010-03-25 2010-03-25
US61/317,351 2010-03-25
PCT/US2010/032477 WO2010126851A1 (en) 2009-04-27 2010-04-27 Cxcr3 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2012525335A JP2012525335A (ja) 2012-10-22
JP2012525335A5 true JP2012525335A5 (enExample) 2013-06-20
JP5741574B2 JP5741574B2 (ja) 2015-07-01

Family

ID=42272001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507474A Expired - Fee Related JP5741574B2 (ja) 2009-04-27 2010-04-27 Ｃｘｃｒ３受容体アンタゴニスト

Country Status (7)

Country Link
US (1) US8362249B2 (enExample)
EP (1) EP2424858B1 (enExample)
JP (1) JP5741574B2 (enExample)
AR (1) AR076460A1 (enExample)
TW (1) TW201103933A (enExample)
UY (1) UY32574A (enExample)
WO (1) WO2010126851A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2809668B1 (en) 2012-02-02 2017-04-12 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
PT2970139T (pt) 2013-03-15 2018-08-01 Biomarin Pharm Inc Inibidores de hdac
WO2014182673A1 (en) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
WO2014182688A1 (en) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
EP3016951B1 (en) 2013-07-02 2017-05-31 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
ES2634628T3 (es) 2013-07-02 2017-09-28 Bristol-Myers Squibb Company Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) * 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
ES2896400T3 (es) * 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
TWI689497B (zh) * 2014-09-04 2020-04-01 南北兄弟藥業投資有限公司 芳雜環類衍生物及其在藥物中的應用
TWI693221B (zh) 2015-01-15 2020-05-11 瑞士商愛杜西亞製藥有限公司 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN120904205A (zh) 2018-08-29 2025-11-07 安塞塔制药公司 制备阿卡拉布替尼的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) * 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
TW200505450A (en) * 2003-02-03 2005-02-16 Janssen Pharmaceutica Nv Quinoline-derived amide modulators of vanilloid VR1 receptor
ZA200800309B (en) * 2005-06-22 2009-10-28 Chemocentryx Inc Azaindazole compounds and methods of use
US20090030012A1 (en) * 2006-02-23 2009-01-29 Adams Alan D Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators
WO2007123269A1 (ja) * 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
JP5286646B2 (ja) * 2006-04-19 2013-09-11 トヨタ自動車株式会社 スルホン基含有モノマーの重合方法
US20090099201A1 (en) * 2007-05-22 2009-04-16 David Robert Bolin Diacylglycerol Acyltransferase Inhibitors
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト

Similar Documents

Publication Publication Date Title
AU2023202592C1 (en) Modulators of the integrated stress pathway
AU2017261336B2 (en) Modulators of the integrated stress pathway
ES2540996T3 (es) Compuestos de N-(1H-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos como inhibidores de tirosina cinasa del receptor de tipo III
RU2518089C2 (ru) Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ
CN115003304A (zh) 通过泛素蛋白酶体途径降解btk的双官能化合物
TW202122387A (zh) Mta協同性之prmt5抑制劑
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
AU2019249849A1 (en) BRM targeting compounds and associated methods of use
BR112019012957A2 (pt) derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
JP2012525332A5 (enExample)
BR112019012993A2 (pt) derivados de benzo-oxazol como imunomoduladores
CA3211347A1 (en) Indazole based compounds and associated methods of use
WO2022081976A1 (en) Piperidinyl small molecule degraders of helios and methods of use
TW200530217A (en) Amino-benzazoles as P2Y1 receptor inhibitors
WO2015177326A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
TWI915393B (zh) 作為雄激素受體調節劑的吲哚化合物
BRPI0418082B1 (pt) Derivados de tiazol úteis como antagonistas de receptor de adenosina A2A
JP2012525367A5 (enExample)
CN104428301A (zh) Nampt抑制剂
WO2016106266A1 (en) TGFβ RECEPTOR ANTAGONISTS
JP2011510004A (ja) タンパク質キナーゼ阻害剤及びその使用
WO2013117645A1 (en) Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
AU2017363268A1 (en) Piperazine derivatives as selective HDAC1,2 inhibitors
AU2015402778A1 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
JP2018525377A5 (enExample)